Abstract
Over the last decades estrogen has been recognized to be involved in normal brain function due to its neurothrophic and neuroprotective effects. Estrogen is intimately associated with neuronal survival, mitochondrial function, neuroinflammation and cognition through genomic as well as non-genomic pathways. It is also known that the neuroprotective actions mediated by estrogens are interlinked with the insulin-like growth factor-1 (IGF-1) signaling pathway. This review is mainly devoted to explore the physiological and pathophysiological effects of estrogen and its signaling pathways in the brain. The molecular mechanisms underlying these effects are also debated. Finally, we discuss the potential neuroprotection afforded by estrogens in Alzheimers disease pathophysiology focusing in the “window of opportunity” for the initiation of estrogen therapy as a critical factor in the fight against neurodegeneration.
Keywords: Alzheimer's disease, estrogen, IGF-1, mitochondria, neuroinflammation, neuroprotection
Current Aging Science
Title: Effects of Estrogen in the Brain: Is it a Neuroprotective Agent in Alzheimers Disease?
Volume: 3 Issue: 2
Author(s): Sonia C. Correia, Renato X. Santos, Susana Cardoso, Cristina Carvalho, Maria S. Santos, Catarina R. Oliveira and Paula I. Moreira
Affiliation:
Keywords: Alzheimer's disease, estrogen, IGF-1, mitochondria, neuroinflammation, neuroprotection
Abstract: Over the last decades estrogen has been recognized to be involved in normal brain function due to its neurothrophic and neuroprotective effects. Estrogen is intimately associated with neuronal survival, mitochondrial function, neuroinflammation and cognition through genomic as well as non-genomic pathways. It is also known that the neuroprotective actions mediated by estrogens are interlinked with the insulin-like growth factor-1 (IGF-1) signaling pathway. This review is mainly devoted to explore the physiological and pathophysiological effects of estrogen and its signaling pathways in the brain. The molecular mechanisms underlying these effects are also debated. Finally, we discuss the potential neuroprotection afforded by estrogens in Alzheimers disease pathophysiology focusing in the “window of opportunity” for the initiation of estrogen therapy as a critical factor in the fight against neurodegeneration.
Export Options
About this article
Cite this article as:
C. Correia Sonia, X. Santos Renato, Cardoso Susana, Carvalho Cristina, S. Santos Maria, R. Oliveira Catarina and I. Moreira Paula, Effects of Estrogen in the Brain: Is it a Neuroprotective Agent in Alzheimers Disease?, Current Aging Science 2010; 3 (2) . https://dx.doi.org/10.2174/1874609811003020113
DOI https://dx.doi.org/10.2174/1874609811003020113 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Glaucoma Pathogenesis and Neurotrophins: Focus on the Molecular and Genetic Basis for Therapeutic Prospects
Current Neuropharmacology T Cell Costimulatory and Inhibitory Receptors as Therapeutic Targets for Inducing Anti-Tumor Immunity
Current Cancer Drug Targets Induction of Synthetic Lethality by Natural Compounds Targeting Cancer Signaling
Current Pharmaceutical Design Survivin as a Prognostic/Predictive Marker and Molecular Target in Cancer Therapy
Current Medicinal Chemistry The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimers Disease
Current Genomics Long Term Ketamine and Ketamine Plus Alcohol Toxicity - What can we Learn from Animal Models?
Mini-Reviews in Medicinal Chemistry Journey Describing the Cytotoxic Potential of Withanolides: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Apoptosis-Inducing Activity of the S100A8/A9 Heterodimer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Molecular Pathology of Eye Tumors: A 2019 Update Main Interests for Routine Clinical Practice
Current Molecular Medicine Functional Role of Glycosphingolipids in Cancer
Current Medicinal Chemistry MDM2 Inhibitors for Pancreatic Cancer Therapy
Mini-Reviews in Medicinal Chemistry Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design Targeting the BH3 Domain of Bcl-2 Family Proteins. A Brief History From Natural Products to Foldamers As Promising Cancer Therapeutic Avenues
Current Medicinal Chemistry From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimer’s Disease
Current Medicinal Chemistry New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer
Current Pharmaceutical Design Targeted Enzyme Prodrug Therapies
Mini-Reviews in Medicinal Chemistry Highly Organized Nanostructures for Brain Drug Delivery - New Hope or Just a Fad?
CNS & Neurological Disorders - Drug Targets Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery p73 as a Pharmaceutical Target for Cancer Therapy
Current Pharmaceutical Design